LeanMed, LLC

Today is our final post in this three part series. You can find the other two posts here https://lnkd.in/gdZejisc and here https://lnkd.in/gjg665fB The Value of Deploying the O2 Cube in Reducing Pediatric Pneumonia Deaths The challenge with existing solutions bringing oxygen to the Last Mile: “PSA plants (~50 cylinders/day, 50L, 150 bar) typically cost USD $100,000, including the plant, cylinder filling station, and shipping. Factoring in additional investments such as a backup generator, pipeline installation, delivery truck, and cylinders, the total cost rises to approximately $350,000. Annual operating expenditures range from 30–70% of the initial investment cost, covering electricity, manpower, and maintenance.” National Strategy on Increasing Access to Medical Oxygen in Rwanda, 2024 Program Description Focus Areas: The primary focus is untreated pediatric pneumonia patients with a secondary focus on other instances of hypoxemia, including pneumonia, bronchiolitis, asthma, chronic obstructive pulmonary disease (COPD), malaria, sepsis, anemia, neonatal asphyxia, respiratory distress, and surgical complications. Deployment Plan: Place an O2 Cube at 10 secondary hospitals, each with at least 5 referring health centers where each O2 Cube can fill five (5) 6.8 cm³ cylinders per week, or approximately 250 annually. per hospital. Treatment Capacity: Each cylinder supports the treatment of two pediatric patients assuming an average treatment of 4 days at 0.5 LPM for neonates or 2 days at 2 LPM for children aged 2–5 years, each clinic treats about 2 children per week. This equates to nearly 5,000 pediatric pneumonia cases treated annually across the program. Impact Calculation: Mortality rate among children diagnosed with hypoxemia is 4% resulting in 200 potential deaths in this example. Years of Life Lost (YLL) equals 200 x 65 years or 13,000 DALYs/year. With a mortality reduction of 49% this results in 98 prevented deaths per year or 6,370 DALY's per year. Cost-Effectiveness: With an annualized operational cost of $90,000 this results in a $14.12 per DALY averted. Conclusion: This small-scale example demonstrates the transformative potential of bridging the last mile of oxygen access globally. By providing medical oxygen in a reliable, cost-effective, and environmentally sustainable manner, the O2 Cube is a critical component of National Medical Oxygen Scale-Up Plans currently under development. hashtag #MissionDrivenInnovation #InvestInOxygen Activate to view larger image,

Yesterday we posted on the “7 Barriers Limiting Oxygen Access for the Last Mile” https://lnkd.in/gwfYcvZC Today we suggest the "7 Ways the O2 Cube Enables Oxygen Access for the Last Mile." Tomorrow I will post an analysis that looks at the social impact of deploying O2 Cubes across an African nation. The O2 Cube is a solar-powered, cloud-connected micro-PSA oxygen production and storage system. It fills cylinders to 2,000 psi at 10 LPM, providing a reliable, sustainable solution for small to mid-sized hospitals in LMICs and their referring health centers. 1. Solar-Powered Freed from reliance on costly, unreliable grid electricity, the O2 Cube operates sustainably in LMICs. 2. Onsite Oxygen Production Its compact design enables placement near healthcare facilities, eliminating transport costs and delays. 3. Affordable Investment At a price point of $20,000, the O2 Cube is a fraction of the cost of a PSA plant, with minimal installation expenses. 4. Low Operating Costs Using sunshine and air, the O2 Cube provides medical oxygen with a carbon-neutral footprint. 5. Scalable Design Facilities can add more O2 Cubes over time, matching production precisely to demand. 6. Rapid Deployment As a standardized product, the O2 Cube can be deployed in one month and installed within a week. 7. Cloud Connectivity Real-time monitoring enables predictive maintenance and operational efficiency. As NGOs and Ministries of Health build their National Medical Oxygen Scale-Up Plans, micro-PSA systems like LeanMed, LLC's #O2Cube must be part of the conversation. Together, we can create a world where no one dies due to a lack of oxygen.

Expanding Access to Medical Oxygen: Addressing the Barriers and Proposing Solutions Recently, prominent organizations such as Unitaid and the Ministry of Health Rwanda have published critical insights on medical oxygen infrastructure. Moreover, the Global Oxygen Alliance, which is hosted by Unitaid, World Health Organization and UNICEF Supply has announced ambitious plans to raise $4 billion to invest in medical oxygen infrastructure. These efforts aim to tackle the alarming fact that one billion people worldwide lack access to medical oxygen, often with devastating consequences. While these developments are promising, they also highlight existing challenges in reaching "The Last Mile"—the underserved communities most in need. Tomorrow, I will share how LeanMed, LLC LLC's solar-powered #O2Cube addresses these challenges. Today, I want to focus on the seven key barriers that current solutions, like PSA plants and stationary oxygen concentrators, face in expanding access to oxygen. 7 Barriers Limiting Oxygen Access for the Last Mile 1. Grid Electricity - Reliable, affordable electricity is scarce in many LMICs (low- and middle-income countries). This increases costs, reduces production efficiency, and can damage equipment like PSA plants and stationary oxygen concentrators that rely on stable power. 2. Roadway Infrastructure - Transporting large cylinders for refill is challenging in areas with underdeveloped roads. Environmental impacts, high costs, and delays due to weather exacerbate the issue. 3. Investment Costs - PSA plants require significant investment, often exceeding $500,000 for procurement and installation. While stationary oxygen concentrators are less costly individually, they have no oxygen storage capacity. 4. Operating Costs - High energy demands, and frequent maintenance make operating PSA plants expensive and challenging. 5. Supply-Demand Mismatch - Many PSA plants are underutilized due to difficulties in aligning supply with fluctuating demand. 6. Time to Production - PSA plants are complex and custom-designed, requiring 6–9 months to deploy—time that many communities don’t have. 7. Lack of Data - PSA plants and stationary oxygen concentrators often lack systems for operational data collection, preventing efficient maintenance and optimization. To be clear, the world needs PSA plants and stationary oxygen concentrators. But we must also acknowledge their limitations and explore how we can economically, environmentally, and logistically serve The Last Mile.

Today at LeanMed, LLC we're proud to announce the formation of LeanMed Africa Ltd. and to introduce its president, Anthony Githinji. Anthony is an experienced healthcare and medical equipment professional with over 2 decades of extensive experience in business development, strategic and operational leadership and management across Africa, Asia and the Americas. As president of #LeanMedAfrica he will lead the penetration and proliferation of oxygen availability via the #O2Cube throughout Africa. Anthony will engage with innovation and investment partners across the globe to deliver medical oxygen via the #O2Cube to the last mile where it is most needed. #missiondriveninnovation https://lnkd.in/g-iEFYvG

LeanMed, LLC is proud to announce our inclusion in the new #Unitaid publication "The Medical Oxygen Innovation Landscape." Once again our unique solar powered medical oxygen production system, the #O2Cube has been recognized as an important solution bringing essential oxygen to those who lack access to it. The report also describes the breakthrough work our Nigerian partner, #HealthPort is doing deploying the O2 Cube in a subscription based hub & spoke business model. #productinnovation #businessmodelinnovation Dr. Aishat Adeniji Better Futures CoLab https://lnkd.in/eyB_ysBq

LeanMed, LLC is part of the Better Futures CoLab program supporting our partners ICChange - Innovative Canadians for Change and HealthPort as they validate the Oxygen-as-a-Service business model. Our contribution is our breakthrough innovation, the #O2Cube. The O2 Cube is a solar powered micro PSA oxygen production system that is bringing medical oxygen to those patients who lack #AccesstoOxygen. Please read this excellent article on the program. It's been an amazing journey using both product and business model innovation to bring oxygen to those that who desperately need it, overcoming economic, environmental and logistical challenges that have plagued existing technology. https://lnkd.in/gZGbQpQW

We're excited to be a part of this program which uses the #O2Cube to extend the reach of medical oxygen.